Apoquel (oclacitinib Tablet) for Dogs, 3.6 mg, 15 Tablets

Apoquel (oclacitinib Tablet) for Dogs, 3.6 mg, 15 Tablets

#1 Prescribed Oral Medicine for Allergic Itch¹: Apoquel is a revolutionary oral medicine for dogs with allergic itch. Apoquel can be used short-term or for long-term maintenance therapy²𝄒³ in dogs 12 months of age and older. Stops Allergic Itch at the Source⁴: Apoquel is not a steroid, antihistamine, or cyclosporine (a type of drug that reduces immune system activity). Apoquel is in a different category of medications. Unlike other medicines, Apoquel blocks allergic itch at the source. So, it works at the underlying cause of itch to provide relief fast. Fast-Acting Allergy Itch Relief: If your dog is scratching, licking, or chewing like crazy, you want to provide fast, effective relief. Apoquel Tablets start relieving allergic itch within 4 hours⁵ and control it within 24 hours². Apoquel has been prescribed to over 14 million dogs and counting.⁶ Can be used with many other medications³ including: nonsteroidal anti-inflammatory drugs (NSAIDs), vaccines (such as rabies), and allergen-specific immunotherapy (allergy shots or drops). The use of Apoquel has not been evaluated in combination with other systemic immunosuppressants, such as corticosteroids and cyclosporine. Available in Three Strengths: Apoquel Tablets come in 3.6 mg, 5.4 mg, and 16 mg based on your dog’s body weight. Follow your veterinarian’s instructions for dosing as prescribed. You can administer to your dog orally once a day with or without food. Apoquel is now available in a pork-liver flavored chewable. Apoquel Tablets control itching (pruritis) associated with allergic dermatitis and control atopic dermatitis in dogs at least 12 months of age. Apoquel has been prescribed for over 14 million dogs⁶ and is #1 in pet owner and vet satisfaction for oral medications for allergic itch in dogs*.⁷𝄒⁸ It goes right to the source to help stop itching and relieve associated inflammation in affected canines providing relief in as little as 4 hours.⁵ Apoquel is given twice daily for up to 14 days, and then given once daily for maintenance therapy. You can use for both short-term or long-term therapy in your dog and discontinue use without tapering. Since Apoquel is neither a steroid nor an antihistamine, your dog will avoid many of the unpleasant side effects that are often associated with these medications. In a 5-year safety review, the most common individual side effects reported with Apoquel were vomiting, diarrhea, lethargy, anorexia, and bloodwork changes.⁹ The most common reported side-effects occurred at a rate of less than one dog reacting out of 10,000 dogs treated.¹⁰ Apoquel Chewable (oclacitinib chewable tablet) is now available and is another easy-to-administer option if your dog is difficult to pill. Both Apoquel Tablet and Apoquel Chewable are available by prescription only. Talk to your veterinarian about which is best for your dog.

References:
*Vets, n=250, Pet Owners, n=491
1. Data on file, PetTrak Total Unique Patient Count, December 2022, Zoetis Inc. (TI-09437)
2. Data on file: Study Report A161C-US-21-C02, Zoetis Inc., 2022 (TI-09898)
3. Cosgrove SB, Cleaver DM, King VL, et al. Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life. Vet Dermatol. 2015;26(3):171-179, e35. doi:10.1111/vde.12194 (AR-01949)
4. Data on file: Study Report A461N-US-21-B66, Zoetis Inc. 2022
5. FOI Apoquel Chewable FOI Summary: 2023/06/09 Original NADA 141-555 (v2.0).
6. Gonzales AJ, Bowman JW, Fici GJ, et al. Oclacitinib (APOQUEL)is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J Vet Pharmacol Therapy. 2014;37(4)317-24. doi:10.1111/jvp.12101 (AR-00542)
7. Data on file, Apoquel Cytopoint Vet Tracker Wave 11 (December 20 2018) (TI-04447)
8. Data on file, APOQUEL/CYTOPOINT Pet Owner Tracker Wave 11, 2022, Zoetis Inc. (TI- 08418)
9. Data on file. A Five-Year Post-Approval Safety Review for Apoquel in the US (May 2013 to August 2018), Zoetis Inc (TI-04506)
10. Volume 6C Summary of the Product Characteristics: SPC European Commission, Brussels. 1 Vol. 6C. July 10, 2006, 1-11. (AR-08728)